PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2016161410) TREATMENT OF CANCER USING INHIBITORS OF TGF-BETA AND PD-1
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2016/161410 International Application No.: PCT/US2016/025802
Publication Date: 06.10.2016 International Filing Date: 03.04.2016
IPC:
C07K 16/22 (2006.01) ,C07K 16/28 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
22
against growth factors
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
XOMA TECHNOLOGY LTD.; 2910 Seventh Street Berkeley, 94710, US
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street 12th Floor Oakland, CA 94607, US
Inventors:
MIRZA, Amer, M.; US
AKHURST, Rosemary, J.; US
LI, Ou; US
Agent:
NEVILLE, Katherine, L.; US
Priority Data:
62/143,01603.04.2015US
62/191,79713.07.2015US
Title (EN) TREATMENT OF CANCER USING INHIBITORS OF TGF-BETA AND PD-1
(FR) TRAITEMENT DU CANCER À L'AIDE D'INHIBITEURS DE TGF-BÊTA ET PD-1
Abstract:
(EN) The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFP) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
(FR) La présente invention concerne, en général, une polythérapie utilisant un inhibiteur du facteur de croissance transformant bêta (TGFP) et un inhibiteur de la protéine de mort cellulaire programmée 1 (PD-1) pour le traitement du cancer ou la prévention de la récurrence de maladies cancéreuses, telles que le cancer du poumon, le cancer de la prostate, le cancer du sein, le cancer hépatocellulaire, le cancer de l'œsophage, le cancer colorectal, le cancer du pancréas, le cancer de la vessie, le cancer du rein, le cancer de l'ovaire, le cancer de l'estomac, le cancer fibrotique, le gliome et le mélanome, et leurs métastases.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3277716CN108136001JP2018518454